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Introduction 
Pembrolizumab is a humanized IgG4 monoclonal 
antibody directed against the programmed death 
cell receptor 1 (PD-1), a major checkpoint in the 
effector phase of cytotoxic T cells. It has 
demonstrated promising clinical results in 
melanoma immunotherapy [1].  
Vitiligo, a clinically visible immune-related adverse 
event, has been associated with clinical benefit in the 
context of pembrolizumab treatment. This 
dermatosis, has been reported as a secondary effect 
in 11%-25% of the patients treated with 
pembrolizumab [2]. Most of the published cases are 
associated with generalized vitíligo. However, we 
present a case of depigmentation at the site of 
primary melanoma and in the areas of in-transit 
metastases, as a graphic representation of the 
appearance of vitiligo-like lesions linked to a 
complete response to treatment with 
pembrolizumab. 
 
Case Synopsis 
An 82-year-old woman diagnosed with BRAF 
negative nodular melanoma and Breslow thickness 
of 3.9mm on her left foot with wide excision and 
negative sentinel node presented with in-transit 
Abstract 
Anti-programmed cell death (PD)-1 therapies in 
metastatic tumors have a high incidence of immune 
adverse events, including cutaneous manifestations 
such as vitiligo-like lesions. This side effect is 
associated with increased survival and it is a clinical 
marker of response to treatment. This case report is a 
graphic representation of the appearance of vitiligo-
like lesions over in-transit metastases of malignant 
melanoma linked to a complete response to 
treatment with pembrolizumab. 
Figure 1. A) Melanoma in situ with in-transit metastases, graft 
scar on foot and wide resection of cutaneous metastases of 
lateral malleolus, before pembrolizumab treatment. B) Vitiligo-
like lesions developed over cutaneous metastases after 
pembrolizumab immunotherapy. 
A B 
Volume 25 Number 12| December 2019| 
25(12):12 
 
 
- 2 - 
Dermatology Online Journal  ||  Letter 
metastases. After six months of follow-up new 
tumors of the external malleolus and the pretibial 
region of her left leg developed. These were treated 
with extensive surgery (Figure 1A). Two years later, 
the patient presented with progression of her 
metastatic disease with an increase in the number of 
in-transit metastases. In addition, a PET CT scan 
showed involvement of left supraclavicular, 
mediastinal, left inguinal, and pulmonary hilum 
lymph nodes. 
Treatment with pembrolizumab 2mg/kg was 
initiated, and after 12 cycles a complete clinical and 
PET-CT scan response was demonstrated. During the 
follow-up, vitiligo-like lesions developed in the area 
of the primary tumor and in the areas of in-transit 
metastases, the appearance of these lesions were 
associated with the complete response in the 
imaging tests (Figure 1B). 
 
Case Discussion 
The treatments with anti-PD1 and anti-CTLA4 
antibodies have revolutionized the management of 
metastatic melanoma and are increasingly used in 
advanced solid organ tumors. The most common 
adverse side effects of PD-1 inhibitors include 
maculopapular rash, pruritus, vitíligo, and lichenoid 
and mucosal skin reactions [3]. The appearance of 
autoimmune diseases, such as the development of 
vitiligo-like lesions associated with pembrolizumab 
immunotherapy, has already been correlated with 
improved survival rates [2, 4, 5]. It has recently been 
shown that this hypopigmentation is biologically 
different from classic vitiligo because they are often 
located in photoexposed areas and do not present 
the Koebner phenomenon. In addition, patients who 
have developed this vitíligo-like hypopigmentation 
while undergoing immunotherapy have had no 
increased personal or family medical history of 
autoimmune diseases [6]. The most accepted 
hypothesis is that it could result from an immune-
mediated destruction through recognition of 
melanoma-associated antigens shared by normal 
melanocytes and melanoma cells. PD-1 antibodies 
activate the immune response by preventing an 
inhibitory signal and probably induce responses 
against antigens shared by melanomas and normal 
melanocytes [2, 7]. Recently it has been 
demonstrated by skin samples and blood analysis a 
strong infiltrate of CXCR3 expressing CD8 T cells and 
elevated levels of interferon-γ and tumor necrosis 
factor. 
Generalized (acrofacial, classic, and universal) and 
localized vitiligo (focal and segmental) are the 
phenotypes of vitíligo-like lesions associated with 
pembrolizumab treatment. At present, two cases 
have been published, such as the one we have 
described around cutaneous metastases [2, 6]. 
 
Conclusion 
This case shows vitíligo-like hypopigmentation that 
particularly involved the sites of in-transit metastases 
in association with complete clinical response.  
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